REFERENCES
1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:548-67.
2. Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res 2018;78:2449-56.
3. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol ;2018:237-44.
4. Plackett B. Will the reclassification of multiple myeloma change how people are treated? Nature 2020;587:S56-7.
5. Robiou du Pont S, Cleynen A, Fontan C, et al. Genomics of multiple myeloma. J Clin Oncol 2017;35:963-7.
6. Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010;116:2543-53.
7. Szalat R, Avet-Loiseau H, Munshi NC. Gene expression profiles in myeloma: ready for the real world? Clin Cancer Res 2016;22:5434-42.
8. Chng WJ, Chung TH, Kumar S, et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia 2016;30:1071-8.
9. Chng WJ, Dispenzieri A, Chim CS, et al. International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269-77.
10. Abdallah N, Rajkumar SV, Greipp P, et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J 2020;10:82.
11. Liu Y, Yu H, Yoo S, et al. A network analysis of multiple myeloma related gene signatures. Cancers (Basel) 2019;11:1452.
12. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 2015;5:e365.
13. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011;204:3-12.
14. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
15. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
16. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863-9.
18. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia 2008;22:459-61.
19. Shaughnessy JD Jr, Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011;118:3512-24.
20. Decaux O, Lodé L, Magrangeas F, et al. Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008;26:4798-805.
21. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88.
22. Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010;16:1856-64.
23. Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012;26:2406-13.
24. Zamani-Ahmadmahmudi M, Nassiri SM, Soltaninezhad F. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma. Br J Haematol 2021;192:310-21.
25. Kuiper R, van Duin M, van Vliet MH, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015;126:1996-2004.
26. Biran N, Dhakal B, Lentzsch S, et al. SKY92 impacts treatment plan in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. SSRN Journal .
27. Kuiper R, van Vliet MH, van Duin M, et al. Gene expression classifier EMC92/SKY92 and revised ISS robustly identify high-risk multiple myeloma in elderly patients of the HOVON-87/NMSG-18 study. Haematologica 2017;102:269-70.
28. Kuiper R, Zweegman S, van Duin M, et al. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. Blood Adv 2020;4:6298-309.
29. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 2008;18:1509-17.
30. Settino M, Arbitrio M, Scionti F, et al. . MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers. In: Krzhizhanovskaya VV, Závodszky G, Lees MH, Dongarra JJ, Sloot PMA, Brissos S, Teixeira J, editors. Computational Science - ICCS 2020. Cham: Springer International Publishing; 2020. p. 564-71.
31. Van Vliet MH, Kuiper R, Dumee B, et al. Single sample application of the EMC92/SKY92 signature using the Mmprofiler. Blood 2014;124:2026.
32. van Beers EH, Huigh D, Bosman L, et al. Analytical validation of SKY92 for the identification of high-risk multiple myeloma. J Mol Diagn 2021;23:120-9.
33. Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. Immunotargets Ther 2020;9:201-15.
34. Thorsteinsdottir S, Dickman PW, Landgren O, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 2018;103:e412-5.
35. Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 2015;18:18-35.
36. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-8.
37. Harding T, Baughn L, Kumar S, Van Ness B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 2019;33:863-83.
38. Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev 2018;70:199-208.
39. Kumar S, Vij R, Kaufman JL, et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Blood 2016;128:488.
40. Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 Selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther 2016;15:1132-44.
41. Mitra AK, Harding T, Mukherjee UK, et al. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 2017;7:e581.
42. de Boussac H, Bruyer A, Jourdan M, et al. Kinome expression profiling to target new therapeutic avenues in multiple myeloma. Haematologica 2020;105:784-95.
43. Herviou L, Kassambara A, Boireau S, et al. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenetics 2018;10:121.
